We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Biomarkers-Based Test to Enable Rapid Diagnosis and Treatment of Tuberculosis

By LabMedica International staff writers
Posted on 21 Jun 2023

Contrary to popular belief, tuberculosis, caused by the bacterium Mycobacterium tuberculosis, is far from eradicated. More...

In fact, according to the World Health Organization (WHO), tuberculosis claims approximately 1.5 million lives annually, making it the deadliest infectious disease in many parts of the world. Prompt detection and treatment of the disease are critical, both for patient health and to prevent further spread, particularly in regions with insufficient infrastructure. The current gold standard for tuberculosis testing relies on a bacterial culture of patients' sputum samples. This method, however, has several limitations, including prolonged wait times for results and a lack of sensitivity and accuracy. Now, a new study has found that biomarkers in the blood can be used to diagnose tuberculosis rapidly and accurately.

Biomarkers are measurable biological components in the blood that provide insight into the body's immune processes at a particular stage. The immune response triggered by a tuberculosis infection can be indicated by specific biomarkers, suggesting a person may have tuberculosis. Researchers at the University of Oslo (Oslo, Norway) and Stellenbosch University (Stellenbosch, South Africa) conducted a collaborative study by analyzing blood samples from patients both with and without tuberculosis in South Africa and Norway to evaluate the diagnostic potential of known biomarkers. The results showed that most biomarkers accurately indicated the presence of tuberculosis, in line with findings from previous studies.

Furthermore, the research team discovered that combinations of different biomarkers yielded superior performance compared to individual biomarkers. The study also explored the use of biomarkers to track antibiotic treatment effectiveness in often severely ill and hospitalized tuberculosis patients. By utilizing various statistical methods, the researchers observed changes in selected immune-related blood biomarkers' concentrations from the beginning of treatment through two weeks, two months, and six months of therapy. These observations underscored the potential of these biomarkers in monitoring treatment response. Based on the biomarkers examined in the study, the researchers believe that it is possible to develop new and better tuberculosis tests. Such tests could be particularly vital in areas severely impacted by the disease and lacking adequate infrastructure.

“The results from our study are promising. They show that the biomarkers we investigated have good diagnostic value for tuberculosis,” said Bih Hycenta Chendi, a researcher at Stellenbosch University. “Such a tool will ensure that we can make the diagnosis quickly and easily. It can also help reduce the number of undiagnosed cases and those affected can receive faster treatment. In particular, the gains will be large in African environments with few resources.”

Related Links:
University of Oslo 
Stellenbosch University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Connectivity Solution
EKF Link
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.